XML 18 R7.htm IDEA: XBRL DOCUMENT
v3.24.3

REVENUE | 9 Months Ended
--- | ---
Sep. 30, 2024
Revenue from Contract with Customer [Abstract] |
REVENUE | REVENUE The following table summarizes the disaggregation of revenue by nature:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2024 |  | 2023 |  | 2024 |  | 2023
Net product sales | $ | 11,483 |  |  | $ | 10,645 |  |  | $ | 34,967 |  |  | $ | 32,610 |
Alliance revenues | 105 |  |  | 138 |  |  | 355 |  |  | 461 |
Other revenues | 304 |  |  | 183 |  |  | 636 |  |  | 458 |
Total Revenues | $ | 11,892 |  |  | $ | 10,966 |  |  | $ | 35,958 |  |  | $ | 33,529 |
The following table summarizes GTN adjustments:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2024 |  | 2023 |  | 2024 |  | 2023
Gross product sales | $ | 21,223 |  |  | $ | 18,648 |  |  | $ | 61,298 |  |  | $ | 54,047 |
GTN adjustments(a) |  |  |  |  |  |  |
Charge-backs and cash discounts | (2,967) |  |  | (2,373) |  |  | (8,366) |  |  | (6,743) |
Medicaid and Medicare rebates | (4,577) |  |  | (3,730) |  |  | (11,525) |  |  | (9,355) |
Other rebates, returns, discounts and adjustments | (2,196) |  |  | (1,900) |  |  | (6,440) |  |  | (5,339) |
Total GTN adjustments(b) | (9,740) |  |  | (8,003) |  |  | (26,331) |  |  | (21,437) |
Net product sales | $ | 11,483 |  |  | $ | 10,645 |  |  | $ | 34,967 |  |  | $ | 32,610 |
(a) Includes reductions to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $42 million and $103 million for the three and nine months ended September 30, 2024 and $18 million and $116 million for the three and nine months ended September 30, 2023, respectively. (b) Includes U.S. GTN adjustments of $8.9 billion and $23.9 billion for the three and nine months ended September 30, 2024 and $7.3 billion and $19.2 billion for the three and nine months ended September 30, 2023, respectively. The following table summarizes the disaggregation of revenue by product and region:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2024 |  | 2023 |  | 2024 |  | 2023
Growth Portfolio |  |  |  |  |  |  |
Opdivo | $ | 2,360 |  |  | $ | 2,275 |  |  | $ | 6,825 |  |  | $ | 6,622 |
Orencia | 936 |  |  | 925 |  |  | 2,682 |  |  | 2,616 |
Yervoy | 642 |  |  | 579 |  |  | 1,855 |  |  | 1,672 |
Reblozyl | 447 |  |  | 248 |  |  | 1,226 |  |  | 688 |
Opdualag | 233 |  |  | 166 |  |  | 674 |  |  | 437 |
Abecma | 124 |  |  | 93 |  |  | 301 |  |  | 372 |
Zeposia | 147 |  |  | 123 |  |  | 408 |  |  | 301 |
Breyanzi | 224 |  |  | 92 |  |  | 484 |  |  | 263 |
Camzyos | 156 |  |  | 68 |  |  | 379 |  |  | 143 |
Sotyktu | 66 |  |  | 66 |  |  | 163 |  |  | 107 |
Augtyro | 10 |  |  | — |  |  | 23 |  |  | — |
Krazati | 34 |  |  | — |  |  | 87 |  |  | — |
Other Growth products(a) | 433 |  |  | 311 |  |  | 1,093 |  |  | 886 |
Total Growth Portfolio | 5,812 |  |  | 4,946 |  |  | 16,200 |  |  | 14,107 |
Legacy Portfolio |  |  |  |  |  |  |
Eliquis | 3,002 |  |  | 2,705 |  |  | 10,138 |  |  | 9,332 |
Revlimid | 1,412 |  |  | 1,429 |  |  | 4,434 |  |  | 4,647 |
Pomalyst/Imnovid | 898 |  |  | 872 |  |  | 2,722 |  |  | 2,551 |
Sprycel | 290 |  |  | 517 |  |  | 1,088 |  |  | 1,404 |
Abraxane | 253 |  |  | 260 |  |  | 701 |  |  | 757 |
Other Legacy products(b) | 225 |  |  | 237 |  |  | 675 |  |  | 731 |
Total Legacy Portfolio | 6,080 |  |  | 6,020 |  |  | 19,758 |  |  | 19,422 |
Total Revenues | $ | 11,892 |  |  | $ | 10,966 |  |  | $ | 35,958 |  |  | $ | 33,529 |
United States | $ | 8,232 |  |  | $ | 7,542 |  |  | $ | 25,509 |  |  | $ | 23,298 |
International | 3,389 |  |  | 3,239 |  |  | 9,803 |  |  | 9,716 |
Other(c) | 271 |  |  | 185 |  |  | 646 |  |  | 515 |
Total Revenues | $ | 11,892 |  |  | $ | 10,966 |  |  | $ | 35,958 |  |  | $ | 33,529 |
(a) Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues. (b) Includes other mature brands. (c) Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations. Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation. Revenue recognized from performance obligations satisfied in prior periods was $238 million and $496 million for the three and nine months ended September 30, 2024 and $114 million and $355 million for the three and nine months ended September 30, 2023, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration